BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function

  1. Xuetian Yue
  2. Yuhan Zhao
  3. Juan Liu
  4. Cen Zhang
  5. Haiyang Yu
  6. Jiabei Wang
  7. Tongsen Zheng
  8. Lianxin Liu
  9. Jun Li
  10. Zhaohui Feng
  11. Wenwei Hu  Is a corresponding author
  1. Rutgers University Newark Campus, United States
  2. Harbin Medical University, China

Abstract

Tumor suppressor p53 is the most frequently mutated gene in tumors. Many mutant p53 (mutp53) proteins promote tumorigenesis through the gain-of-function (GOF) mechanism. Mutp53 proteins often accumulate to high levels in tumors, which is critical for mutp53 GOF. Its underlying mechanism is poorly understood. Here, we found that BAG2, a protein of Bcl-2 associated athanogene (BAG) family, promotes mutp53 accumulation and GOF in tumors. Mechanically, BAG2 binds to mutp53 and translocates to the nucleus to inhibit the MDM2-mutp53 interaction, and MDM2-mediated ubiquitination and degradation of mutp53. Thus, BAG2 promotes mutp53 accumulation and GOF in tumor growth, metastasis and chemoresistance. BAG2 is frequently overexpressed in tumors. BAG2 overexpression is associated with poor prognosis in patients and mutp53 accumulation in tumors. These findings revealed a novel and important mechanism for mutp53 accumulation and GOF in tumors, and also uncovered an important role of BAG2 in tumorigenesis through promoting mutp53 accumulation and GOF.

Article and author information

Author details

  1. Xuetian Yue

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Yuhan Zhao

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Juan Liu

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Cen Zhang

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Haiyang Yu

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Jiabei Wang

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Tongsen Zheng

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Lianxin Liu

    Key laboratory of hepatosplenic surgery, Harbin Medical University, Harbin, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Jun Li

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Zhaohui Feng

    Rutgers University Newark Campus, New Brunswick, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Wenwei Hu

    Rutgers University Newark Campus, New Brunswick, United States
    For correspondence
    wh221@cinj.rutgers.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Carol Prives, Columbia University, United States

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocol (#I13-028) of Rutgers University.

Version history

  1. Received: May 1, 2015
  2. Accepted: August 12, 2015
  3. Accepted Manuscript published: August 13, 2015 (version 1)
  4. Version of Record published: September 8, 2015 (version 2)

Copyright

© 2015, Yue et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,959
    views
  • 667
    downloads
  • 60
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Xuetian Yue
  2. Yuhan Zhao
  3. Juan Liu
  4. Cen Zhang
  5. Haiyang Yu
  6. Jiabei Wang
  7. Tongsen Zheng
  8. Lianxin Liu
  9. Jun Li
  10. Zhaohui Feng
  11. Wenwei Hu
(2015)
BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function
eLife 4:e08401.
https://doi.org/10.7554/eLife.08401

Share this article

https://doi.org/10.7554/eLife.08401

Further reading

    1. Cell Biology
    Joanne Tung, Lei Huang ... Adriana Ordonez
    Research Article

    Activating transcription factor 6 (ATF6) is one of three endoplasmic reticulum (ER) transmembrane stress sensors that mediate the unfolded protein response (UPR). Despite its crucial role in long-term ER stress adaptation, regulation of ATF6 alpha (α) signalling remains poorly understood, possibly because its activation involves ER-to-Golgi and nuclear trafficking. Here, we generated an ATF6α/Inositol-requiring kinase 1 (IRE1) dual UPR reporter CHO-K1 cell line and performed an unbiased genome-wide CRISPR/Cas9 mutagenesis screen to systematically profile genetic factors that specifically contribute to ATF6α signalling in the presence and absence of ER stress. The screen identified both anticipated and new candidate genes that regulate ATF6α activation. Among these, calreticulin (CRT), a key ER luminal chaperone, selectively repressed ATF6α signalling: Cells lacking CRT constitutively activated a BiP::sfGFP ATF6α-dependent reporter, had higher BiP levels and an increased rate of trafficking and processing of ATF6α. Purified CRT interacted with the luminal domain of ATF6α in vitro and the two proteins co-immunoprecipitated from cell lysates. CRT depletion exposed a negative feedback loop implicating ATF6α in repressing IRE1 activity basally and overexpression of CRT reversed this repression. Our findings indicate that CRT, beyond its known role as a chaperone, also serves as an ER repressor of ATF6α to selectively regulate one arm of the UPR.

    1. Cancer Biology
    2. Cell Biology
    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.